← All trials
NCT05198752
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 18, 2022
- Primary completion
- Dec 22, 2023
- Completion date
- Jun 12, 2024
- First posted
- Jan 20, 2022
- Last posted
- Oct 17, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stemirna TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.